Eagle Pharmaceuticals Executive Compensation (FY22)
EGRX · Executive and director compensation, fiscal 2022 only
The Eagle Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (DEF 14A): May 1, 2023
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
100 figures on this page, cited to the filing that reported them. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Eagle Pharmaceuticals' chief executive and what were they paid?
Total compensation for Scott Tarriff, President, Chief Executive Officer, Director, came to $10,520,577 in fiscal 2022.
Which companies are in Eagle Pharmaceuticals' peer group?
The disclosed peer group names Agenus, Amphastar Pharmaceuticals, Catalyst Pharmaceuticals, Clovis Oncology and Coherus BioSciences, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Tarriff President, Chief Executive Officer, Director | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Moran Former Chief Commercial Officer Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Brian Cahill Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Brian Cahill | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Brian Cahill | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael Moran | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael Moran | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Scott Tarriff | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Scott Tarriff | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Scott Tarriff | Option | ◇ | — | ◇ | 1/22/2029 |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/4/2030 | |
| RSU | ◇ | ◇ | — | — | |
| Brian Cahill | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 12/17/2030 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/4/2030 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/28/2029 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2022
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Michael Graves Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Steven Ratoff | ◇ | — | ◇ | — | — | — | ◇ |
Robert Glenning | ◇ | — | ◇ | — | — | — | ◇ |
Richard A. Edlin | ◇ | — | ◇ | — | — | — | ◇ |
Luciana Borio | ◇ | — | ◇ | — | — | — | ◇ |
Jennifer K. Simpson | ◇ | — | ◇ | — | — | — | ◇ |
Scott Tarriff served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
- Agenus AGEN
- Amphastar Pharmaceuticals AMPH
- Catalyst Pharmaceuticals CPRX
- Clovis Oncology symbol not shown
- Coherus BioSciences CHRS
- Collegium Pharmaceutical COLL
- Corcept Therapeutics CORT
- Global Blood Therapeutics symbol not shown
- Intercept Pharmaceuticals ICPT
- Lannett Co. symbol not shown
- Ligand Pharmaceuticals LGND
- Nektar Therapeutics NKTR
- Pacira BioSciences PCRX
- Puma Biotechnology PBYI
- Supernus Pharmaceuticals SUPN
- Vanda Pharmaceuticals VNDA
What this page does not include
Everything above is a fact Eagle Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Eagle Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
100 figures on this page, cited to the filing that reported them.
100 cited to the filing
Documents cited
- 0001104659-23-0543382022 Outstanding Equity Awards at Fiscal Year-End Table · Grants of Plan-Based Awards · Grants of Plan-Based Awards for Fiscal Year 2022 Table · Summary Compensation Table · and 1 more section
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Eagle Pharmaceuticals executive compensation, FY2022.” https://intel.velarion.ai/comp/EGRX (accessed 2026).
Short form: data: Velarion
The Eagle Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Eagle Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Eagle Pharmaceuticals discloses
The companies named in EGRX's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}